PATENT CLAIM ANALYSIS

Application Number: 15757012
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["424", "449000"]

Abstract:
The present application is directed to transdermal formulations for the delivery of doxycycline compounds to a subject for the treatment of doxycycline-responsive diseases. In particular, the transdermal formulation is an emulsion comprising an oil phase, an aqueous phase and an external phase.

Claim (Index 15):
The method of  claim 14 , wherein the doxycycline-responsive disease or condition is selected from one or more of diseases and conditions are selected from one or more of Gram-negative and Gram-positive bacterial infections, skin diseases such as acne and rosacea, wrinkles, scleroderma, hyperpigmentation,  Clostridium difficile  colitis, early Lyme disease, malaria, chronic prostatitis, sinusitis and dermal wound healing.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 90.0
- Lexical Diversity: 1.4375
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15623898', '13566816', '12795164', '13732024', '15168542']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7809790833020717
- 35 USC 102 Novelty (BERT): 0.4819601123551429
- Combined Prediction Score: 0.7510771862073788
- Mean Citation Score: 170.051434
- Max Citation Score: 178.84657
- Similarity Product: 128.70377344461622

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test